The systemic or intraperitoneal administration of a recombinant vaccinia OV (vvDD) expressing the chemokine CCL-19 was found to result in enhanced anti-tumour effects in syngeneic mouse tumour models. The gene discussed is CCL19; the disease is neoplasm.